Icahn Turns Up The Heat On Amylin, Urges Board To Sell
This article was originally published in The Pink Sheet Daily
Executive Summary
The activist investor, previously involved in buyouts at ImClone, Biogen Idec and Elan, as well as a proxy fight at Genzyme, scolds Amylin’s board for lack of transparency on purported Bristol offer and asserts the biotech is not positioned to maximize the market potential of Bydureon.